by Portfolio Grader | August 21, 2013 9:00 am
This week, eight Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Insys Therapeutics, Inc. (NASDAQ:INSY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Surprise and Sales Growth, INSY also gets A’s. Shares of INSY have increased 34.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of INSY stock.
This week, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Prana Biotechnology Ltd Sponsored ADR (NASDAQ:PRAN) improves from a B to an A rating this week. Prana Biotechnology is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. The stock’s price of $4.44 is above the 50-day moving average of $2.87. For more information, get Portfolio Grader’s complete analysis of PRAN stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) boosts its rating from a C to a B this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. With a price of $14.48, it is above the 50-day moving average of $13.82. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) shows solid improvement this week. The company’s rating rises from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics, Inc.’s (NASDAQ:CLDX) ratings are looking better this week, moving up to an A from last week’s B. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
The rating of Insmed Incorporated (NASDAQ:INSM) moves up this week, rising from a C to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
This week, Neuralstem, Inc.’s (AMEX:CUR) ratings are up from a C last week to a B. Neuralstem is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the CNS. For more information, get Portfolio Grader’s complete analysis of CUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/08/8-biotechnology-stocks-to-buy-now-insy-aria-pran/
Short URL: http://invstplc.com/1nvSFUE